Anchorage, AKNCT04871542Now EnrollingIRB Ready

Malignant Solid Neoplasm Clinical Trial in Anchorage, AK

Access cutting-edge malignant solid neoplasm treatment through this clinical trial at a research site in Anchorage. Study-provided care at no cost to qualified participants.

Sponsored by SWOG Cancer Research Network

Quick Self-Assessment

See if you qualify for this Anchorage location

Preparing your pre-screening questions…

Expert Care in Anchorage

Access malignant solid neoplasm specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related malignant solid neoplasm treatment provided free

Apply for This Anchorage Location

Check if you qualify for this malignant solid neoplasm clinical trial in Anchorage, AK

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Anchorage

    Convenient for AK residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Anchorage site if eligible
  4. 4Begin participation

About This Malignant Solid Neoplasm Study in Anchorage

This study examines how certain risk factors (such as age, gender, other medical conditions, and the type of immunotherapy used to treat the cancer) affect whether a patient with a malignant solid tumor will develop mild or serious side effects from the immunotherapy medications. Immunotherapy is the type of treatment that helps the body's immune system fight cancer. In the future, this information may help doctors make better decisions about cancer treatments.

Sponsor: SWOG Cancer Research Network

Who Can Participate

Inclusion Criteria

Participants must be planning to receive ICI-based therapy for a solid tumor malignancy. This therapy must be given according to Food and Drug Administration (FDA) label or National Comprehensive Cancer Network (NCCN) guidelines at Category 1 or 2A and not in the context of a clinical trial
Participants who have received prior ICI-based therapy must have completed ICI based therapy at least 180 days prior to registration
Participants must not have discontinued any prior ICI-based therapy (if applicable) because of irAE
Participants must not have received chemotherapy, biologic, or targeted-therapy within 21 days prior to registration
Participants must have recovered from side effects of prior therapy to the following standards per treating physician's discretion:
=\< Grade 1 for any non-hematologic side effects (excluding neuropathy and alopecia); lab-related parameters of liver and renal function will be considered at the discretion of the treating physician)
=\< Grade 2 for neuropathy and/or alopecia
Grade 3 or less for any hematologic side effects
Participants must be planning to begin standard of care ICI-based therapy within 3 calendar days after registration
Participants must not be planning to receive ICI-based therapy in combination with chemotherapy or any other non-ICI therapy for treatment of their cancer
Participants must be at least 18 years of age
Participants must complete their history and physical examination within 28 days prior to registration
Participants who can complete the S2013 Feasibility Questionnaire in English or Spanish must participate at the scheduled assessments
Participants must be able to complete Patient-Reported Outcome (PRO) instruments in English, Spanish, or French and must be planning to complete PROs at all scheduled assessments
Participants must complete the pre-registration (baseline) PRO forms within 14 days prior to registration
Participants must be willing to participate in PRO data collection
Note: Prior to registration, participants must decide on their method (paper or electronic) of completing their follow-up questionnaires. Participants who elect electronic (ePRO) completion must have an iPhone, Android phone, or tablet with cellular or WiFi connectivity in order to download the Patient Cloud mobile applications onto the device (personal device or a site provisioned device for multi-users)
Participants must be offered the opportunity to participate in the optional specimen banking
Note: As a part of the OPEN registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system.
Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Anchorage?

Yes, this clinical trial (NCT04871542) has an active research site in Anchorage, AK that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Malignant Solid Neoplasm Treatment Options in Anchorage, AK

If you're searching for malignant solid neoplasm treatment options in Anchorage, AK, this clinical trial (NCT04871542) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Anchorage research site is actively enrolling participants for this clinical trial. You'll receive care from experienced malignant solid neoplasm specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all malignant solid neoplasm clinical trials near you to find additional studies recruiting in your area.

More Ankylosing Spondylitis Trials in Anchorage, AK

See all ankylosing spondylitis clinical trials recruiting in Anchorage — not just this study.

Browse Ankylosing Spondylitis Trials in Anchorage →

Browse More Trials by Condition

Ankylosing Spondylitis TrialsAll Conditions →

Ready to Join in Anchorage?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Anchorage, AK